Sugi Predict

Sugi Predict / Compounds / SCHEMBL16505656

SCHEMBL16505656

SCHEMBL16505656

CCOC(=O)c1nc(Cl)ncc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ XBP1 P17861 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ TLR9 Q9NR96 1/20 0.49
▸ ATF1 P18846 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ KDM5B Q9UGL1 1/20 0.42
▸ SYK P43405 1/20 0.42
▸ GLP1R P43220 1/20 0.42
▸ TARBP2 Q15633 1/20 0.42
▸ JMJD6 Q6NYC1 1/20 0.41
▸ GABRA2 P47869 2/20 0.40
▸ GABRB2 P47870 2/20 0.40
▸ HPGD P15428 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30339623 0.94 MAPT (0.45) MAPTALDH1A1NPC1TP53XBP1
SCHEMBL21678973 0.84 ALDH1A1 (0.51) MAPTALDH1A1NPC1TP53XBP1
SCHEMBL16709919 0.84 MAPT (0.67) MAPTALDH1A1NPC1TP53XBP1
SCHEMBL30173602 0.84 MAPT (0.67) MAPTALDH1A1NPC1TP53XBP1
SCHEMBL21678987 0.83 ALDH1A1 (0.50) MAPTALDH1A1NPC1TP53XBP1
SCHEMBL8395110 0.83 ALDH1A1 (0.50) MAPTALDH1A1NPC1TP53XBP1
SCHEMBL16094863 0.82 NPSR1 (0.45) ALDH1A1NPSR1HSD17B10ATF1NFKB1
SCHEMBL21679019 0.81 MAPT (0.49) MAPTALDH1A1NPC1TP53XBP1
SCHEMBL4184662 0.81 ALDH1A1 (0.41) MAPTALDH1A1NPC1TP53XBP1
SCHEMBL2521639 0.81 ALDH1A1 (0.49) MAPTALDH1A1NPC1TP53XBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107422-A1 6-(PYRIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE BRISTOL-MYERS SQUIBB COMPANY (US) 2026-05-21 — — WO disclosed
US-12612388-B2 Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas Sironax Ltd. (KY) 2026-04-28 — — US disclosed
WO-2026041663-A1 P2X7 RECEPTOR ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2026-02-26 — — WO disclosed
EP-4674415-A2 AZAQUINOLINES AS INHIBITORS OF CD38 Boehringer Ingelheim International GmbH (DE) 2026-01-07 — — EP disclosed
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 — — US disclosed
EP-4284511-B1 AZAQUINOLINES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2025-07-16 — — EP disclosed
EP-4522608-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2025-03-19 — — EP disclosed
CN-119546602-A Pyrrolidone derivatives as inhibitors of nfkb-induced kinase 詹森药业有限公司 2025-02-28 — — CN disclosed
CN-115697972-B Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide urea 维泰瑞隆有限公司 2024-11-22 — — CN disclosed
WO-2024175925-A1 MC2R MODULATOR COMPOUNDS Omass Therapeutics Limited (GB) 2024-08-29 — — WO disclosed
WO-2017003995-A1 TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-01-05 — — WO disclosed
WO-2017003995-A1 TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-01-05 — — WO disclosed
US-20160376283-A1 TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-12-29 — — US disclosed
US-20160185797-A1 ALKYNYL ALCOHOLS AND METHODS OF USE GENENTECH, INC. (US) 2016-06-30 — — US disclosed
EP-3036229-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2016-06-29 — — EP disclosed
WO-2015025026-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2015-02-26 — — WO disclosed
WO-2015025026-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2015-02-26 — — WO disclosed
US-20150057260-A1 ALKYNYL ALCOHOLS AND METHODS OF USE GENENTECH, INC. (US) 2015-02-26 — — US disclosed
US-20150057260-A1 ALKYNYL ALCOHOLS AND METHODS OF USE GENENTECH, INC. (US) 2015-02-26 — — US disclosed
US-20150057260-A1 ALKYNYL ALCOHOLS AND METHODS OF USE GENENTECH, INC. (US) 2015-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057260-A1 ALKYNYL ALCOHOLS AND METHODS OF USE NFKB2, NFKB1, NFKBIA MAPT 2169/4885ALDH1A1 25/4885NPC1 480/4885
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB MAPT 3311/4885ALDH1A1 4167/4885NPC1 2311/4885
US-20160185797-A1 ALKYNYL ALCOHOLS AND METHODS OF USE NFKB2, NFKB1, NFKBIA MAPT 2169/4885ALDH1A1 25/4885NPC1 480/4885
US-12612388-B2 Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas NCOR1, NCOR2, SUCNR1 MAPT 4153/4885ALDH1A1 4498/4885NPC1 1357/4885
US-20160376283-A1 TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF NFKBIA, TBKBP1, TBK1 MAPT 1388/4885ALDH1A1 4646/4885NPC1 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.